Loading…

Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases

To enable the establishment of a drug discovery operation for neglected diseases, out of 2.3 million commercially available compounds 222 552 compounds were selected for an in silico library, 57 438 for a diverse general screening library, and 1 697 compounds for a focused kinase set. Compiling thes...

Full description

Saved in:
Bibliographic Details
Published in:ChemMedChem 2008-03, Vol.3 (3), p.435-444
Main Authors: Brenk, Ruth, Schipani, Alessandro, James, Daniel, Krasowski, Agata, Gilbert, Ian Hugh, Frearson, Julie, Wyatt, Paul Graham
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c5429-f86ee5f5fb6558953380f261acd6f0cc79e18a61f219b250581ecc894dfb7ce03
cites cdi_FETCH-LOGICAL-c5429-f86ee5f5fb6558953380f261acd6f0cc79e18a61f219b250581ecc894dfb7ce03
container_end_page 444
container_issue 3
container_start_page 435
container_title ChemMedChem
container_volume 3
creator Brenk, Ruth
Schipani, Alessandro
James, Daniel
Krasowski, Agata
Gilbert, Ian Hugh
Frearson, Julie
Wyatt, Paul Graham
description To enable the establishment of a drug discovery operation for neglected diseases, out of 2.3 million commercially available compounds 222 552 compounds were selected for an in silico library, 57 438 for a diverse general screening library, and 1 697 compounds for a focused kinase set. Compiling these libraries required a robust strategy for compound selection. Rules for unwanted groups were defined and selection criteria to enrich for lead‐like compounds which facilitate straightforward structure–activity relationship exploration were established. Further, a literature and patent review was undertaken to extract key recognition elements of kinase inhibitors (“core fragments”) to assemble a focused library for hit discovery for kinases. Computational and experimental characterisation of the general screening library revealed that the selected compounds 1) span a broad range of lead‐like space, 2) show a high degree of structural integrity and purity, and 3) demonstrate appropriate solubility for the purposes of biochemical screening. The implications of this study for compound selection, especially in an academic environment with limited resources, are considered. Drug discovery on a low budget: To enable a drug discovery operation for neglected diseases, a small but diverse high‐throughput library was assembled. The selected compounds span a broad range of lead‐like space, show a high degree of structural integrity and purity, and demonstrate appropriate solubility for the purposes of biochemical screening.
doi_str_mv 10.1002/cmdc.200700139
format article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2628535</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70387616</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5429-f86ee5f5fb6558953380f261acd6f0cc79e18a61f219b250581ecc894dfb7ce03</originalsourceid><addsrcrecordid>eNqFkctv1DAQxq0K1JbClSPKiVuWcRI_cqlUZfsAhaUSj16QLMcZLy5J3NrZwv73ZNnVUk49zWj8-77x6CPkNYUZBcjemb41swxAANC8PCDHVHJIBZXi2b4X5RF5EeMtQFFIKg_JEZXAC07FMfleY4x-iEmNOgxjYoPvk7MYsW86NyyTzyYgDpuudk3QwWFMrA_JPKyWydxF4x8wrP-OFrjs0IzYbuaoI8aX5LnVXcRXu3pCvl6cf6mu0vrT5fvqrE4NK7IytZIjMstswxmTJctzCTbjVJuWWzBGlEil5tRmtGwyBkxSNEaWRWsbYRDyE3K69b1bNT22Bocx6E7dBdfrsFZeO_X_y-B-qKV_UBnPJMvZZPB2ZxD8_QrjqPrpNOw6PaBfRSUgl4JTPoGzLWiCjzGg3S-hoDaBqE0gah_IJHjz-Gv_8F0CE1BugV-uw_UTdqr6OK8em6dbrYsj_t5rdfipuMgFUzeLS_WB3Swqev1NXeV_AARDqPM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>70387616</pqid></control><display><type>article</type><title>Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases</title><source>Wiley-Blackwell Read &amp; Publish Collection</source><creator>Brenk, Ruth ; Schipani, Alessandro ; James, Daniel ; Krasowski, Agata ; Gilbert, Ian Hugh ; Frearson, Julie ; Wyatt, Paul Graham</creator><creatorcontrib>Brenk, Ruth ; Schipani, Alessandro ; James, Daniel ; Krasowski, Agata ; Gilbert, Ian Hugh ; Frearson, Julie ; Wyatt, Paul Graham</creatorcontrib><description>To enable the establishment of a drug discovery operation for neglected diseases, out of 2.3 million commercially available compounds 222 552 compounds were selected for an in silico library, 57 438 for a diverse general screening library, and 1 697 compounds for a focused kinase set. Compiling these libraries required a robust strategy for compound selection. Rules for unwanted groups were defined and selection criteria to enrich for lead‐like compounds which facilitate straightforward structure–activity relationship exploration were established. Further, a literature and patent review was undertaken to extract key recognition elements of kinase inhibitors (“core fragments”) to assemble a focused library for hit discovery for kinases. Computational and experimental characterisation of the general screening library revealed that the selected compounds 1) span a broad range of lead‐like space, 2) show a high degree of structural integrity and purity, and 3) demonstrate appropriate solubility for the purposes of biochemical screening. The implications of this study for compound selection, especially in an academic environment with limited resources, are considered. Drug discovery on a low budget: To enable a drug discovery operation for neglected diseases, a small but diverse high‐throughput library was assembled. The selected compounds span a broad range of lead‐like space, show a high degree of structural integrity and purity, and demonstrate appropriate solubility for the purposes of biochemical screening.</description><identifier>ISSN: 1860-7179</identifier><identifier>EISSN: 1860-7187</identifier><identifier>DOI: 10.1002/cmdc.200700139</identifier><identifier>PMID: 18064617</identifier><language>eng</language><publisher>Weinheim: WILEY-VCH Verlag</publisher><subject>Chemistry, Pharmaceutical - methods ; Combinatorial Chemistry Techniques - methods ; compound selection ; Databases, Factual ; Drug Design ; high-throughput screening ; kinase inhibitors ; neglected diseases ; Peptide Library ; Pharmaceutical Preparations - analysis ; Pharmaceutical Preparations - chemistry ; Protein Kinase Inhibitors - chemistry ; Protein Kinase Inhibitors - pharmacology ; Structure-Activity Relationship ; virtual screening</subject><ispartof>ChemMedChem, 2008-03, Vol.3 (3), p.435-444</ispartof><rights>Copyright © 2008 WILEY‐VCH Verlag GmbH &amp; Co. KGaA, Weinheim</rights><rights>Copyright © 2008 WILEY-VCH Verlag GmbH &amp; Co. KGaA, Weinheim</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5429-f86ee5f5fb6558953380f261acd6f0cc79e18a61f219b250581ecc894dfb7ce03</citedby><cites>FETCH-LOGICAL-c5429-f86ee5f5fb6558953380f261acd6f0cc79e18a61f219b250581ecc894dfb7ce03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,777,781,882,27906,27907</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18064617$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Brenk, Ruth</creatorcontrib><creatorcontrib>Schipani, Alessandro</creatorcontrib><creatorcontrib>James, Daniel</creatorcontrib><creatorcontrib>Krasowski, Agata</creatorcontrib><creatorcontrib>Gilbert, Ian Hugh</creatorcontrib><creatorcontrib>Frearson, Julie</creatorcontrib><creatorcontrib>Wyatt, Paul Graham</creatorcontrib><title>Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases</title><title>ChemMedChem</title><addtitle>ChemMedChem</addtitle><description>To enable the establishment of a drug discovery operation for neglected diseases, out of 2.3 million commercially available compounds 222 552 compounds were selected for an in silico library, 57 438 for a diverse general screening library, and 1 697 compounds for a focused kinase set. Compiling these libraries required a robust strategy for compound selection. Rules for unwanted groups were defined and selection criteria to enrich for lead‐like compounds which facilitate straightforward structure–activity relationship exploration were established. Further, a literature and patent review was undertaken to extract key recognition elements of kinase inhibitors (“core fragments”) to assemble a focused library for hit discovery for kinases. Computational and experimental characterisation of the general screening library revealed that the selected compounds 1) span a broad range of lead‐like space, 2) show a high degree of structural integrity and purity, and 3) demonstrate appropriate solubility for the purposes of biochemical screening. The implications of this study for compound selection, especially in an academic environment with limited resources, are considered. Drug discovery on a low budget: To enable a drug discovery operation for neglected diseases, a small but diverse high‐throughput library was assembled. The selected compounds span a broad range of lead‐like space, show a high degree of structural integrity and purity, and demonstrate appropriate solubility for the purposes of biochemical screening.</description><subject>Chemistry, Pharmaceutical - methods</subject><subject>Combinatorial Chemistry Techniques - methods</subject><subject>compound selection</subject><subject>Databases, Factual</subject><subject>Drug Design</subject><subject>high-throughput screening</subject><subject>kinase inhibitors</subject><subject>neglected diseases</subject><subject>Peptide Library</subject><subject>Pharmaceutical Preparations - analysis</subject><subject>Pharmaceutical Preparations - chemistry</subject><subject>Protein Kinase Inhibitors - chemistry</subject><subject>Protein Kinase Inhibitors - pharmacology</subject><subject>Structure-Activity Relationship</subject><subject>virtual screening</subject><issn>1860-7179</issn><issn>1860-7187</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><recordid>eNqFkctv1DAQxq0K1JbClSPKiVuWcRI_cqlUZfsAhaUSj16QLMcZLy5J3NrZwv73ZNnVUk49zWj8-77x6CPkNYUZBcjemb41swxAANC8PCDHVHJIBZXi2b4X5RF5EeMtQFFIKg_JEZXAC07FMfleY4x-iEmNOgxjYoPvk7MYsW86NyyTzyYgDpuudk3QwWFMrA_JPKyWydxF4x8wrP-OFrjs0IzYbuaoI8aX5LnVXcRXu3pCvl6cf6mu0vrT5fvqrE4NK7IytZIjMstswxmTJctzCTbjVJuWWzBGlEil5tRmtGwyBkxSNEaWRWsbYRDyE3K69b1bNT22Bocx6E7dBdfrsFZeO_X_y-B-qKV_UBnPJMvZZPB2ZxD8_QrjqPrpNOw6PaBfRSUgl4JTPoGzLWiCjzGg3S-hoDaBqE0gah_IJHjz-Gv_8F0CE1BugV-uw_UTdqr6OK8em6dbrYsj_t5rdfipuMgFUzeLS_WB3Swqev1NXeV_AARDqPM</recordid><startdate>20080314</startdate><enddate>20080314</enddate><creator>Brenk, Ruth</creator><creator>Schipani, Alessandro</creator><creator>James, Daniel</creator><creator>Krasowski, Agata</creator><creator>Gilbert, Ian Hugh</creator><creator>Frearson, Julie</creator><creator>Wyatt, Paul Graham</creator><general>WILEY-VCH Verlag</general><general>WILEY‐VCH Verlag</general><scope>BSCLL</scope><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20080314</creationdate><title>Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases</title><author>Brenk, Ruth ; Schipani, Alessandro ; James, Daniel ; Krasowski, Agata ; Gilbert, Ian Hugh ; Frearson, Julie ; Wyatt, Paul Graham</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5429-f86ee5f5fb6558953380f261acd6f0cc79e18a61f219b250581ecc894dfb7ce03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Chemistry, Pharmaceutical - methods</topic><topic>Combinatorial Chemistry Techniques - methods</topic><topic>compound selection</topic><topic>Databases, Factual</topic><topic>Drug Design</topic><topic>high-throughput screening</topic><topic>kinase inhibitors</topic><topic>neglected diseases</topic><topic>Peptide Library</topic><topic>Pharmaceutical Preparations - analysis</topic><topic>Pharmaceutical Preparations - chemistry</topic><topic>Protein Kinase Inhibitors - chemistry</topic><topic>Protein Kinase Inhibitors - pharmacology</topic><topic>Structure-Activity Relationship</topic><topic>virtual screening</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Brenk, Ruth</creatorcontrib><creatorcontrib>Schipani, Alessandro</creatorcontrib><creatorcontrib>James, Daniel</creatorcontrib><creatorcontrib>Krasowski, Agata</creatorcontrib><creatorcontrib>Gilbert, Ian Hugh</creatorcontrib><creatorcontrib>Frearson, Julie</creatorcontrib><creatorcontrib>Wyatt, Paul Graham</creatorcontrib><collection>Istex</collection><collection>Wiley Online Library</collection><collection>Wiley Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>ChemMedChem</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Brenk, Ruth</au><au>Schipani, Alessandro</au><au>James, Daniel</au><au>Krasowski, Agata</au><au>Gilbert, Ian Hugh</au><au>Frearson, Julie</au><au>Wyatt, Paul Graham</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases</atitle><jtitle>ChemMedChem</jtitle><addtitle>ChemMedChem</addtitle><date>2008-03-14</date><risdate>2008</risdate><volume>3</volume><issue>3</issue><spage>435</spage><epage>444</epage><pages>435-444</pages><issn>1860-7179</issn><eissn>1860-7187</eissn><abstract>To enable the establishment of a drug discovery operation for neglected diseases, out of 2.3 million commercially available compounds 222 552 compounds were selected for an in silico library, 57 438 for a diverse general screening library, and 1 697 compounds for a focused kinase set. Compiling these libraries required a robust strategy for compound selection. Rules for unwanted groups were defined and selection criteria to enrich for lead‐like compounds which facilitate straightforward structure–activity relationship exploration were established. Further, a literature and patent review was undertaken to extract key recognition elements of kinase inhibitors (“core fragments”) to assemble a focused library for hit discovery for kinases. Computational and experimental characterisation of the general screening library revealed that the selected compounds 1) span a broad range of lead‐like space, 2) show a high degree of structural integrity and purity, and 3) demonstrate appropriate solubility for the purposes of biochemical screening. The implications of this study for compound selection, especially in an academic environment with limited resources, are considered. Drug discovery on a low budget: To enable a drug discovery operation for neglected diseases, a small but diverse high‐throughput library was assembled. The selected compounds span a broad range of lead‐like space, show a high degree of structural integrity and purity, and demonstrate appropriate solubility for the purposes of biochemical screening.</abstract><cop>Weinheim</cop><pub>WILEY-VCH Verlag</pub><pmid>18064617</pmid><doi>10.1002/cmdc.200700139</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1860-7179
ispartof ChemMedChem, 2008-03, Vol.3 (3), p.435-444
issn 1860-7179
1860-7187
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2628535
source Wiley-Blackwell Read & Publish Collection
subjects Chemistry, Pharmaceutical - methods
Combinatorial Chemistry Techniques - methods
compound selection
Databases, Factual
Drug Design
high-throughput screening
kinase inhibitors
neglected diseases
Peptide Library
Pharmaceutical Preparations - analysis
Pharmaceutical Preparations - chemistry
Protein Kinase Inhibitors - chemistry
Protein Kinase Inhibitors - pharmacology
Structure-Activity Relationship
virtual screening
title Lessons Learnt from Assembling Screening Libraries for Drug Discovery for Neglected Diseases
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T08%3A24%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Lessons%20Learnt%20from%20Assembling%20Screening%20Libraries%20for%20Drug%20Discovery%20for%20Neglected%20Diseases&rft.jtitle=ChemMedChem&rft.au=Brenk,%20Ruth&rft.date=2008-03-14&rft.volume=3&rft.issue=3&rft.spage=435&rft.epage=444&rft.pages=435-444&rft.issn=1860-7179&rft.eissn=1860-7187&rft_id=info:doi/10.1002/cmdc.200700139&rft_dat=%3Cproquest_pubme%3E70387616%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c5429-f86ee5f5fb6558953380f261acd6f0cc79e18a61f219b250581ecc894dfb7ce03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=70387616&rft_id=info:pmid/18064617&rfr_iscdi=true